We help CROs and trial service providers cut document and outreach workload and prepare better for sponsor conversations, while recruitment decisions, source data and protocol deviations stay reviewable by qualified people.
AI works best on bounded document and communication tasks: drafting proposals and sponsor reports, gathering feasibility research, supporting query creation and sending approved recruitment outreach. Evidence that AI improves enrollment fairly and at scale is thin. Recruitment decisions, source data and protocol deviations must stay reviewable under good clinical practice, so qualified people approve what matters.
Sponsors compare CROs on cost, therapeutic experience and timelines. Each request for proposal means rebuilding past performance, staffing assumptions and feasibility into a fresh document, usually under a tight deadline.
Choosing countries and sites depends on incomplete historical data and the judgment of experienced operations staff. A poor choice shows up months later as slow enrollment.
Ads and outreach must stay within approved materials, platform health ad policies and consent rules for calls and texts. A headline that asks a viewer whether they have a condition can breach platform policy by itself.
Protocols, amendments, monitoring reports and correspondence must stay version-controlled and reviewable. Any AI-generated text is one more record to control.
Sponsors expect regular, accurate updates on enrollment, deviations and risks. Compiling them from trackers, issue logs and monitoring notes is slow and easy to get subtly wrong.
Established means widely deployed and well documented. Emerging means real deployments exist but results vary with your data and workflow. Early means pilots or research, not a safe default.
AI drafts first versions of bid sections from an approved library of past responses, capability statements and standard text. Business development and operations leads check every claim about experience, staffing and timelines. Drafting and summarizing are among the better-established uses.
AI assembles enrollment figures, monitoring notes and issue logs into a draft update for the project manager, who verifies numbers against the source systems. The quality of the draft depends on how clean those systems are, which is a data integration question.
A 2026 review lists protocol and study-document drafting, and data monitoring and query creation, as documented applications. We treat drafts as working material for medical writers and data managers, never as controlled documents until reviewed under your procedures.
Email and text sequences that use only approved wording, route questions to site coordinators and honor opt-outs. The AI does not write new claims or screen eligibility. Channel rules sit with digital marketing and the sponsor's approval route.
Matching is a documented application, but it is distinct from proof that autonomous recruitment improves enrollment fairly. We would use it to suggest leads that site staff review, and test who is and is not being surfaced.
AI can gather registry listings, publications and your own past performance data into a briefing for the feasibility lead. We do not claim a validated way to predict site performance, so any ranking is a prompt for experienced judgment.
The principal investigator and site coordinators decide who is approached, screened and enrolled. AI never decides eligibility.
The clinical operations lead and data manager keep source data, protocol deviations and any AI-generated records reviewable.
The QA lead decides which AI uses sit inside your procedures, how outputs are versioned and when SOPs change.
The business development director and operations lead verify every statement of experience and capacity in a proposal before it leaves.
Bid teams start from checked text instead of old documents, so editing time goes to the sponsor's specific questions.
Project managers spend more time on risks and decisions and less on re-keying numbers, provided source systems are consistent.
Every outreach message uses wording that has been through the approval route, with questions routed to a named coordinator.
Each request for proposal is tracked from receipt to outcome, so win and loss reasons are recorded instead of remembered.
A CRO's revenue depends on winning bids, delivering to plan and being invited back. AI that shortens bid assembly and keeps sponsor communication consistent helps with the first and third, while delivery performance still decides the second. Revenue operations gives the bid pipeline the discipline other sectors apply to sales.
General information for planning, not legal advice. Statuses and dates are as published at the time of writing.
Build an approved response library and a bid tracker. Measure drafting time and edit load on a few live proposals, with humans verifying every claim.
Pick one stable program and automate the first draft of its sponsor update. The project manager checks every figure against the source systems.
List each AI use, decide which touch controlled documents or source data, and set review and versioning rules with your QA lead. This is the core of AI governance for a CRO.
No. Eligibility and enrollment decisions stay with the investigator and site team. AI can suggest leads for review, but our sources do not show that autonomous recruitment is fair or effective.
Not on the evidence we rely on. A 2026 review documents applications such as patient-to-trial matching, but that is different from proof of better enrollment. A 2025 survey of 302 respondents found 30.3% beginning or piloting and 22.1% partially implementing AI across trial activities.
The sources we rely on do not describe it as an AI rule. The practical point is that recruitment decisions, source data and protocol deviations, including AI-generated records, must remain reviewable. It took effect in the EU in July 2025, and FDA issued final guidance in September 2025.
It can draft variants, but only approved wording should go live. Platform health policies, consent rules for calls and texts, and sponsor approvals all apply. Health details entered in screening forms should not reach advertising platforms.
It shortens first drafts and keeps tracking consistent, so your team spends more time on the sponsor's real questions. Sponsors still choose on experience and delivery record, and device sponsors and drug sponsors weigh these differently.
Bring one proposal process or one recurring sponsor report. We will show where AI fits, where it does not and what your quality system needs to cover. Book a discovery call to review it with us.